Literature DB >> 1516054

Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study.

R M Pascale1, V Marras, M M Simile, L Daino, G Pinna, S Bennati, M Carta, M A Seddaiu, G Massarelli, F Feo.   

Abstract

Previous work has shown a consistent fall in S-adenosyl-L-methionine (SAM) in the liver of diethylnitrosamine-initiated rats, during the development of preneoplastic lesions, in persistent nodules (PNs), and hepatocellular carcinomas. The injection of SAM into rats causes the reconstitution of the SAM pool, coupled with growth restraint, remodeling, and apoptosis of preneoplastic cells, and inhibits the development of PNs and hepatocellular carcinomas. To evaluate if SAM treatment causes a long-term prevention of preneoplastic and neoplastic liver lesions or merely causes a delay in their development, we evaluated the effect of a relatively short SAM treatment on the development of preneoplastic and neoplastic lesions in a long-term study. Male Wistar rats were subjected to initiation with diethylnitrosamine, followed by selection and then by the administration of phenobarbital for 16 weeks. After selection, the rats were given i.m. injections of a purified SAM preparation (384 mumol/kg/day) for 24 weeks. In SAM-treated rats, a decrease in the incidence of PNs was found 6, 14, and 24-28 months after initiation. At the end of SAM treatment the number of PNs per rat liver, nodule diameter, and labeling and mitotic indices of nodular cells decreased considerably in control rats. Nodule diameter started to increase rapidly again only 8 months after arresting SAM treatment, when complete recovery of DNA synthesis in nodular cells occurred. The majority of nodules present in the liver 6-28 months after initiation belonged to the clear and acidophilic cell types, with lower percentages of mixed cell and basophilic cell types. A decrease in basophilic nodules occurred in SAM-treated rats. Fourteen and 24-28 months after initiation hepatocellular carcinoma incidence was 11 of 12 and 10 of 10 in control rats, respectively, and only 1 of 12 and 3 of 11 in SAM-treated rats. At the 24th-28th month all control rats had tumors identified as 2 poorly differentiated carcinomas, 6 trabecular carcinomas, or 3 adenocarcinomas, while only 2 relatively small trabecular carcinomas and 1 small glandular tumor developed in SAM-treated rats. In 3 of 11 SAM-treated rats, but in none of the control rats, leukemic infiltration of liver occurred 24-28 months after initiation. Leukemic infiltration of the spleen occurred in 5 and 3 control and SAM-treated rats, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516054

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  SAMe and HuR in liver physiology: usefulness of stem cells in hepatic differentiation research.

Authors:  Laura Gomez-Santos; Mercedes Vazquez-Chantada; Jose Maria Mato; Maria Luz Martinez-Chantar
Journal:  Methods Mol Biol       Date:  2012

2.  MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.

Authors:  Maria M Simile; Graziella Peitta; Maria L Tomasi; Stefania Brozzetti; Claudio F Feo; Alberto Porcu; Antonio Cigliano; Diego F Calvisi; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2019-04-19

Review 3.  Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2012-09-26       Impact factor: 7.376

4.  Evidence for LKB1/AMP-activated protein kinase/ endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine, and nitric oxide in hepatocyte proliferation.

Authors:  Mercedes Vázquez-Chantada; Usue Ariz; Marta Varela-Rey; Nieves Embade; Nuria Martínez-Lopez; David Fernández-Ramos; Laura Gómez-Santos; Santiago Lamas; Shelly C Lu; M Luz Martínez-Chantar; José M Mato
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

5.  S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.

Authors:  Shelly C Lu; Komal Ramani; Xiaopeng Ou; Mark Lin; Victor Yu; Kwangsuk Ko; Ryan Park; Teodoro Bottiglieri; Hidekazu Tsukamoto; Gary Kanel; Samuel W French; José M Mato; Rex Moats; Edward Grant
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

6.  The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.

Authors:  Matthew Wortham; Lin He; Maxwell Gyamfi; Bryan L Copple; Yu-Jui Yvonne Wan
Journal:  Dig Dis Sci       Date:  2008-02-26       Impact factor: 3.199

7.  A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma.

Authors:  Covadonga Huidobro; Estela G Toraño; Agustín F Fernández; Rocío G Urdinguio; Ramón M Rodríguez; Cecilia Ferrero; Pablo Martínez-Camblor; Loreto Boix; Jordi Bruix; Juan Luís García-Rodríguez; Marta Varela-Rey; José María Mato; María Luz Martínez-Chantar; Mario F Fraga
Journal:  J Mol Med (Berl)       Date:  2013-03-12       Impact factor: 4.599

Review 8.  S-Adenosylmethionine in cell growth, apoptosis and liver cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  J Gastroenterol Hepatol       Date:  2008-03       Impact factor: 4.029

Review 9.  S-adenosylmethionine metabolism and liver disease.

Authors:  José M Mato; M Luz Martínez-Chantar; Shelly C Lu
Journal:  Ann Hepatol       Date:  2013 Mar-Apr       Impact factor: 2.400

10.  Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma.

Authors:  Vishnudutt Purohit; Rao Rapaka; Oh Sang Kwon; B J Song
Journal:  Life Sci       Date:  2012-10-30       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.